DMT for Healthy Volunteers

31 papers and 16 clinical trials exploring dmt as a treatment for healthy volunteers.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 300 million people affected by depression worldwide.

Healthy Volunteers

Research involving healthy volunteers has expanded to investigate the therapeutic potentials of various psychedelics for mental health conditions. Recent findings, emphasizing compounds like psilocybin and DMT, illustrate a promising future for psychedelic-assisted therapies.

Full Healthy Volunteers profile

Academic Research

31 papers
Open Accessindividual

Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways

In a within-subject pharmacoimaging study of 11 healthy psychedelic-experienced volunteers, inhaled DMT acutely reduced connectivity between the left ventral tegmental area and the right nucleus accumbens while increasing connectivity between the nucleus accumbens and anterior cingulate cortex and between the medial prefrontal cortex and anterior cingulate. These connectivity shifts correlated with changes in volition and perception and suggest a potential therapeutic mechanism for disorders of reward processing.

Published
Journal
Scientific Reports
Authors
Lima, G., Soares, C., Teixeira, M., Pais, M., Cabral, C., Rijo, P., Castelo-Branco, M.
Open Accessindividual

A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer

In a randomized, placebo‑controlled ascending‑dose study in 48 healthy volunteers, single IV doses of GM‑2505 up to 20 mg were well tolerated and showed dose‑proportional pharmacokinetics (t1/2 40–50 min) with dose‑dependent neuroendocrine, neurophysiological and subjective psychedelic effects, including decreased theta/alpha and increased gamma EEG power. The duration of cardiovascular and subjective effects was intermediate between psilocybin and DMT, indicating a practical 10–15 mg IV dose range for supervised clinical use.

Published
Journal
Journal of Psychopharmacology
Authors
Austin, E. W., Borghans, L. G. J. M., Christian, E. P., Dvorak, D., Hughes, Z. A., Jacobs, G., Juachon, M. J., Klein, A. K., Krol, F. J., Kruegel, A. C., Leong, W., Makai-Bölöni, S., Marek, G. J., Otto, M. E., Raines, S., Sporn, J., Umbricht, D., van der Graaf, A. J., Winters, J.
Open Accessindividual

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

In this open-label exploratory crossover study of nine experienced ayahuasca users, three Acacia‑derived oral formulations delivering DMT plus harmala alkaloids were well tolerated, produced no clinically significant physiological changes, and elicited psychedelic effects rated comparable to (and for ACL‑010 sometimes more beneficial than) traditional ayahuasca. These findings suggest Acacia‑based DMT/harmala formulations are a feasible alternative for future clinical trials, although generalisability is limited by the small sample size and open‑label design.

Published
Journal
Frontiers in Psychiatry
Authors
Bonomo, Y. A., Collins, L., Dwyer, J., Norman, A. F., Perkins, D., Ross, M., Sarris, J.
Open Accessindividual

Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects

This secondary of a single-blind, randomised study (n=16) using DMT (0-120mg) with harmine (0-180mg) in an ayahuasca-inspired (‘pharmahuasca’) formulation found that harmine significantly enhanced DMT bioavailability and prolonged absorption, resulting in higher sustained plasma concentrations and increased subjective psychedelic effects, with population pharmacokinetic/pharmacodynamic modeling revealing substantial interindividual variability in clearance, bioavailability, and sensitivity to psychedelic effects.

Published
Journal
Biomedicine & Pharmacotherapy
Authors
Äbelö, A., Ashton, M., Dornbierer, D. A., Egger, K., Scheidegger, M., Smallridge, J. W., van Rotz, R.
Open Accessindividual

Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects

In a randomised, double‑blind, placebo‑controlled within‑subjects trial in 31 healthy volunteers, an ayahuasca‑inspired N,N‑DMT plus harmine formulation produced acute increases in mindfulness and both self‑ and other‑directed compassion one day after dosing compared with harmine or placebo, with larger effects in high‑sensitivity individuals. These findings suggest the formulation may have therapeutic potential similar to traditional ayahuasca and warrant further clinical investigation.

Published
Journal
Journal of Psychopharmacology
Authors
Aicher, H. D., Dornbierer, D. A., Meling, D., Mueller, M. J., Scheidegger, M., Wicki, I.
Open Accessindividual

Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT

The three-item Peak Experience Scale (PES) reliably and rapidly measures the strength of 5‑MeO‑DMT experiences, showing dose-related increases, a single PCA component explaining 83.5% of variance, high internal consistency (α = 0.896) and strong correlations with established measures (MEQ-30, EDI, 5D-ASC) but not the CEQ. The authors conclude the PES could be used to gain fast insight into psychedelic intensity in individual patients and to guide dose and re-dose decisions for rapid-acting psychedelics.

Published
Journal
Frontiers in Psychology
Authors
Mason, N. L., Ramaekers, J. G., Reckweg, J., Svendsen, C. B., Terwey, T. H., Theunissen, E. L.

Clinical Trials

16 trials

Explore further

Search all DMT papers Search all Healthy Volunteers trials Full DMT profile Full Healthy Volunteers profile